Singapore
SCG Cell Therapy is a biotechnology company headquartered in Singapore that strives to lead the next wave of biotech breakthroughs. Established in 2017, the company combines regional advantages in Singapore, China, and Germany, covering the entire value chain from innovative drug research and discovery to manufacturing, clinical development, and commercialization.
Specializing in the development of novel immunotherapies in infections and associated cancers, SCG targets common cancer-causing infections such as helicobacter pylori, human papillomavirus, and hepatitis B. The company boasts a unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections, aiming to prevent and cure associated cancers.
Collaborating with leading scientists and researchers, SCG strives to bring first-in-class medical products and technologies to enhance innovation in medical product development. The most recent milestone for SCG is the $8.10M Series C investment received on 05 April 2023 from Smartech Investment Holdings.
